Application of a decision support tool for anticoagulation in patients with non-valvular atrial fibrillation

Journal of General Internal Medicine

Volumn 23, Issue 4, 2008, Pages 411-417

  Wess, Mark L ^a   Schauer, Daniel P ^a   Johnston, Joseph A ^a,b   Moomaw, Charles J ^a   Brewer, David E ^a   Cook, E Francis ^c   Eckman, Mark H ^a  

^a UNIVERSITY OF CINCINNATI MEDICAL CENTER   (United States)

^b US Outcomes Research   (United States)

^c HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

Anticoagulation; Atrial fibrillation; Decision aid; Decision support

Indexed keywords

WARFARIN;

ADULT; AGED; ANTICOAGULANT THERAPY; ANTICOAGULATION; ARTICLE; BRAIN HEMORRHAGE; COHORT ANALYSIS; COMPARATIVE STUDY; COMPUTER; CONTROLLED STUDY; DECISION SUPPORT SYSTEM; FEMALE; GASTROINTESTINAL HEMORRHAGE; HAZARD; HAZARD RATIO; HEART ATRIUM FIBRILLATION; HUMAN; MALE; MEDICAID; OBSERVATIONAL STUDY; OUTCOME ASSESSMENT; PREDICTOR VARIABLE; PROPORTIONAL HAZARDS MODEL; RETROSPECTIVE STUDY; RISK; RISK BENEFIT ANALYSIS; STATISTICAL SIGNIFICANCE; STROKE; UNITED STATES;

AGED; AGED, 80 AND OVER; ANTICOAGULANTS; ATRIAL FIBRILLATION; COHORT STUDIES; DECISION SUPPORT SYSTEMS, CLINICAL; FEMALE; HUMANS; INTERNATIONAL NORMALIZED RATIO; MALE; MEDICAID; MEDICAL AUDIT; MEDICAL ORDER ENTRY SYSTEMS; MIDDLE AGED; OHIO; PHYSICIAN'S PRACTICE PATTERNS; PROPORTIONAL HAZARDS MODELS; RETROSPECTIVE STUDIES; STROKE; UNITED STATES; WARFARIN;

EID: 41549093733     PISSN: 08848734     EISSN: 15251497     Source Type: Journal    
DOI: 10.1007/s11606-007-0477-9     Document Type: Article

References (52)

1. Laupacis A, Boysen G, Connolly S, et al. Risk factors for stroke and efficacy of antithrombotic therapy in atrial fibrillation. Analysis of pooled data from five randomized controlled trials. Arch Intern Med. 1994;154(13):1449-57.
2. Ruigomez A, Johansson S, Wallander MA, Rodriguez LA. Incidence of chronic atrial fibrillation in general practice and its treatment pattern. J Clin Epidemiol. 2002;55(4):358-63.
3. Wolf PA, Abbott RD, Kannel WB. Atrial fibrillation as an independent risk factor for stroke: the Framingham Study. Stroke. 1991;22(8):983-8.
4. Singer DE. Overview of the randomized trials to prevent stroke in atrial fibrillation. Ann Epidemiol. 1993;3(5):563-7.
5. The Boston Area Anticoagulation Trial for Atrial Fibrillation Investigators. The effect of low-dose warfarin on the risk of stroke in patients with nonrheumatic atrial fibrillation. N Engl J Med. 1990;323(22):1505-11.
6. EAFT (European Atrial Fibrillation Trial) Study Group. Secondary prevention in non-rheumatic atrial fibrillation after transient ischaemic attack or minor stroke. Lancet. 1993;342(8882):1255-62.
7. Petersen P, Boysen G, Godtfredsen J, Andersen ED, Andersen B. Placebo-controlled, randomised trial of warfarin and aspirin for prevention of thromboembolic complications in chronic atrial fibrillation. The Copenhagen AFASAK study. Lancet. 1989;1(8631):175-9.
8. Stroke Prevention in Atrial Fibrillation Study Investigators. Stroke Prevention in Atrial Fibrillation Study: final results. Circulation. 1991;84(2):527-39.
9. Connolly SJ, Laupacis A, Gent M, Roberts RS, Cairns JA, Joyner C. Canadian Atrial Fibrillation Anticoagulation (CAFA) Study. J Am Coll Cardiol. 1991;18(2):349-55.
10. Ezekowitz MD, Bridgers SL, James KE, Carliner NH, Colling CL, Gornick CC, et al. Warfarin in the prevention of stroke associated with nonrheumatic atrial fibrillation. Veterans Affairs Stroke Prevention in Nonrheumatic Atrial Fibrillation Investigators. N Engl J Med. 1992;327(20):1406-12.
11. Singer DE, Hughes RA, Gress D, Sheehan MA, Oertel LB, Maraventano SW, et al. The effect of aspirin on the risk of stroke in patients with nonrheumatic atrial fibrillation: The BAATAF Study. Am Heart J. 1992;124(6):1567-73.
12. Go AS, Hylek EM, Borowsky LH, Phillips KA, Selby JV, Singer DE. Warfarin use among ambulatory patients with nonvalvular atrial fibrillation: the anticoagulation and risk factors in atrial fibrillation (ATRIA) study. Ann Intern Med. 1999;131(12):927-34.
13. Gottlieb LK, Salem-Schatz S. Anticoagulation in atrial fibrillation. Does efficacy in clinical trials translate into effectiveness in practice. Arch Intern Med. 1994;154(17):1945-53.
14. Stafford RS, Singer DE. Recent national patterns of warfarin use in atrial fibrillation. Circulation. 1998;97(13):1231-3.
15. Bungard TJ, Ghali WA, Teo KK, McAlister FA, Tsuyuki RT. Why do patients with atrial fibrillation not receive warfarin. Arch Intern Med. 2000;160(1):41-6.
16. Samsa GP, Matchar DB, Goldstein LB, Bonito AJ, Lux LJ, Witter DM, et al. Quality of anticoagulation management among patients with atrial fibrillation: results of a review of medical records from 2 communities. Arch Intern Med. 2000;160(7):967-73.
17. Device may reduce stroke risk from chronic atrial fibrillation. Mayo Clin Health Lett. 2006;24(1):4.
18. Fang MC, Stafford RS, Ruskin JN, Singer DE. National trends in antiarrhythmic and antithrombotic medication use in atrial fibrillation. Arch Intern Med. 2004;164(1):55-60.
19. Johnston JA, Cluxton RJ Jr, Heaton PC, Guo JJ, Moomaw CJ, Eckman MH. Predictors of warfarin use among Ohio Medicaid patients with new-onset nonvalvular atrial fibrillation. Arch Intern Med. 2003;163(14):1705-10.
20. Reynolds M, Shah J, Essebag V, Olshansky B, Friedman PA, Hadjis T, et al. Patterns and predictors of warfarin use in patients with new-onset atrial fibrillation from the FRACTAL Registry. Am J Cardiol. 2006;97(4):538-43.
21. Hylek EM, Singer DE. Risk factors for intracranial hemorrhage in outpatients taking warfarin. Ann Intern Med. 1994;120(11):897-902.
22. Fang MC, Chang Y, Hylek EM, Rosand J, Greenberg SM, Go AS, et al. Advanced age, anticoagulation intensity, and risk for intracranial hemorrhage among patients taking warfarin for atrial fibrillation. Ann Intern Med. 2004;141(10):745-52.
23. Levine MN, Raskob G, Beyth RJ, Kearon C, Schulman S. Hemorrhagic complications of anticoagulant treatment: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest. 2004;126(3 Suppl):287S-310S.
24. Singer DE, Albers GW, Dalen JE, Go AS, Halperin JL, Manning WJ. Antithrombotic therapy in atrial fibrillation: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest. 2004;126(3 Suppl):429S-56S.
25. Albers GW, Dalen JE, Laupacis A, Manning WJ, Petersen P, Singer DE. Antithrombotic therapy in atrial fibrillation. Chest. 2001;119(1 Suppl):194S-206S.
26. Fuster V, Ryden LE, Cannom DS, Crijns HJ, Curtis AB, Ellenbogen KA, et al. ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation-executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of Patients With Atrial Fibrillation). J Am Coll Cardiol. 2006;48(4):854-906.
27. Cohen N, Almoznino-Sarafian D, Alon I, Gorelik O, Koopfer M, Chachashvily S, et al. Warfarin for stroke prevention still underused in atrial fibrillation: patterns of omission. Stroke. 2000;31(6):1217-22.
28. Beyth RJ, Antani M, Covinsky KE, Miller DG, Chren MM, Quinn LM, et al. Why isn't warfarin prescribed to patients with nonrheumatic atrial fibrillation. J Gen Intern Med. 1996;11(12):721-8.
29. Gage BF, Boechler M, Doggette AL, Fortune G, Flaker GC, Rich MW, et al. Adverse outcomes and predictors of underuse of antithrombotic therapy in Medicare beneficiaries with chronic atrial fibrillation. Stroke. 2000;31(4):822-7.
30. Singer DE, Go AS. Antithrombotic therapy in atrial fibrillation. Clin Geriatr Med. 2001;17(1):131-47.
31. Hart RG, Benavente O, McBride R, Pearce LA. Antithrombotic therapy to prevent stroke in patients with atrial fibrillation: a meta-analysis. Ann Intern Med. 1999;131(7):492-501.
32. Koroukian SM, Cooper GS, Rimm AA. Ability of Medicaid claims data to identify incident cases of breast cancer in the Ohio Medicaid population. Health Serv Res. 2003;38(3):947-60.
33. Shireman TI, Heaton PC, Gay WE, Cluxton RJ, Moomaw CJ. Relationship between asthma drug therapy patterns and healthcare utilization. Ann Pharmacother. 2002;36(4):557-64.
34. Landefeld CS, Anderson PA, Goodnough LT, Moir TW, Hom DL, Rosenblatt MW, et al. The bleeding severity index: validation and comparison to other methods for classifying bleeding complications of medical therapy. J Clin Epidemiol. 1989;42(8):711-8.
35. Beyth RJ, Quinn LM, Landefeld CS. Prospective evaluation of an index for predicting the risk of major bleeding in outpatients treated with warfarin. Am J Med. 1998;105(2):91-9.
36. Eckman MH. Patient-centered decision making: a view of the past and a look toward the future. Med Decis Mak. 2001;21(3):241-7.
37. Johnston JA, Eckman MH. Use of regression modeling to simulate patient-specific decision analysis for patients with nonvalvular atrial fibrillation. Med Decis Mak. 2003;23(5):361-8.
38. Eckman MH, Pauker SG, eds. Decision Analytical Issues in the Management of Atrial Fibrillation. Philadelphia, PA: Lippincott-Raven Publishers; 1997.
39. Eckman MH, Levine HJ, Salem DN, Pauker SG. Making decisions about antithrombotic therapy in heart disease: decision analytic and cost-effectiveness issues. Chest. 1998;114(5 Suppl):699S-714S.
40. Eckman MH, Falk RH, Pauker SG. Cost-effectiveness of therapies for patients with nonvalvular atrial fibrillation. Arch Intern Med. 1998;158(15):1669-77.
41. Landefeld CS, Goldman L. Major bleeding in outpatients treated with warfarin: incidence and prediction by factors known at the start of outpatient therapy. Am J Med. 1989;87(2):144-52.
42. Rosenbaum PR. Observational Studies. 2nd ed. New York, NY: Spinger; 2002.
43. Eckman MH, Rosand J, Knudsen KA, Singer DE, Greenberg SM. Can patients be anticoagulated after intracerebral hemorrhage? A decision analysis. Stroke. 2003;34(7):1710-6.
44. Fang MC, Go AS, Hylek EM, Chang Y, Henault LE, Jensvold NG, et al. Age and the risk of warfarin-associated hemorrhage: the anticoagulation and risk factors in atrial fibrillation study. J Am Geriatr Soc. 2006;54(8):1231-6.
45. Rosand J, Eckman MH, Knudsen KA, Singer DE, Greenberg SM. The effect of warfarin and intensity of anticoagulation on outcome of intracerebral hemorrhage. Arch Intern Med. 2004;164(8):880-4.
46. Lip GY, Edwards SJ. Stroke prevention with aspirin, warfarin and ximelagatran in patients with non-valvular atrial fibrillation: a systematic review and meta-analysis. Thromb Res. 2006;118:321-33.
47. Sam C, Massaro JM, D'Agostino RB Sr, Levy D, Lambert JW, Wolf PA, et al. Warfarin and aspirin use and the predictors of major bleeding complications in atrial fibrillation (the Framingham Heart Study). Am J Cardiol. 2004;94(7):947-51.
48. Gage BF, van Walraven C, Pearce L, Hart RG, Koudstaal PJ, Boode BS, et al. Selecting patients with atrial fibrillation for anticoagulation: stroke risk stratification in patients taking aspirin. Circulation. 2004;110(16):2287-92.
49. Walkup JT, Boyer CA, Kellermann SL. Reliability of Medicaid claims files for use in psychiatric diagnoses and service delivery. Adm Policy Ment Health. 2000;27(3):129-39.
50. Hennessy S, Bilker WB, Weber A, Strom BL. Descriptive analyses of the integrity of a US Medicaid claims database. Pharmacoepidemiol Drug Saf. 2003;12(2):103-11.
51. Twiggs JE, Fifield J, Apter AJ, Jackson EA, Cushman RA. Stratifying medical and pharmaceutical administrative claims as a method to identify pediatric asthma patients in a Medicaid managed care organization. J Clin Epidemiol. 2002;55(9):938-44.
52. Glynn RJ, Monane M, Gurwitz JH, Choodnovskiy I, Avorn J. Agreement between drug treatment data and a discharge diagnosis of diabetes mellitus in the elderly. Am J Epidemiol. 1999;149(6):541-9.